<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Biotia</title>
    <link>https://www.biospace.com/employer/3076391/biotia</link>
    <description>Biotia</description>
    <language>en-US</language>
    <lastBuildDate>Thu, 19 Nov 2020 13:16:08 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/3076391/biotia.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Twist Bioscience and Biotia Announce Research Use Only Availability of First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay for Characterization and Surveillance of the Virus</title>
      <link>https://www.biospace.com/twist-bioscience-and-biotia-announce-research-use-only-availability-of-first-hybridization-capture-based-next-generation-sequencing-sars-cov-2-assay-for-characterization-and-surveillance-of-the-virus</link>
      <description>Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today announced the availability of an important new research tool for the sequencing and surveillance of COVID-19.</description>
      <pubDate>Thu, 19 Nov 2020 13:16:08 GMT</pubDate>
      <guid>https://www.biospace.com/twist-bioscience-and-biotia-announce-research-use-only-availability-of-first-hybridization-capture-based-next-generation-sequencing-sars-cov-2-assay-for-characterization-and-surveillance-of-the-virus</guid>
    </item>
    <item>
      <title>Twist Bioscience and Biotia Receive U.S. FDA Emergency Use Authorization for First Hybridization Capture-Based Next-Generation Sequencing SARS-CoV-2 Assay</title>
      <link>https://www.biospace.com/twist-bioscience-and-biotia-receive-u-s-fda-emergency-use-authorization-for-first-hybridization-capture-based-next-generation-sequencing-sars-cov-2-assay</link>
      <description>Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Biotia, Inc., a company that uses proprietary analytical software for infectious disease diagnostics, today received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 Next-Generation Sequencing (NGS) Assay.</description>
      <pubDate>Wed, 24 Mar 2021 11:16:05 GMT</pubDate>
      <guid>https://www.biospace.com/twist-bioscience-and-biotia-receive-u-s-fda-emergency-use-authorization-for-first-hybridization-capture-based-next-generation-sequencing-sars-cov-2-assay</guid>
    </item>
    <item>
      <title>Biotia's Newest Software for SARS-CoV-2 Genetic Surveillance Sees Rapid Adoption By Researchers Seeking Deeper Insights</title>
      <link>https://www.biospace.com/biotia-s-newest-software-for-sars-cov-2-genetic-surveillance-sees-rapid-adoption-by-researchers-seeking-deeper-insights</link>
      <description>Biotia, Inc., a company that delivers proprietary analytical software for infectious disease diagnostics, is experiencing rapid adoption by clinical researchers worldwide of its user-friendly software platform for the comprehensive surveillance and deeper insights into COVID-19 viral genetic variants.</description>
      <pubDate>Wed, 08 Sep 2021 12:06:17 GMT</pubDate>
      <guid>https://www.biospace.com/biotia-s-newest-software-for-sars-cov-2-genetic-surveillance-sees-rapid-adoption-by-researchers-seeking-deeper-insights</guid>
    </item>
    <item>
      <title>Twist Bioscience and Biotia Receive Expanded Emergency Use Authorization to Report Genetic Variants of SARS-CoV-2</title>
      <link>https://www.biospace.com/twist-bioscience-and-biotia-receive-expanded-emergency-use-authorization-to-report-genetic-variants-of-sars-cov-2</link>
      <description>Twist Bioscience and Biotia Receive Expanded Emergency Use Authorization to Report Genetic Variants of SARS-CoV-2.</description>
      <pubDate>Tue, 02 Aug 2022 12:06:24 GMT</pubDate>
      <guid>https://www.biospace.com/twist-bioscience-and-biotia-receive-expanded-emergency-use-authorization-to-report-genetic-variants-of-sars-cov-2</guid>
    </item>
    <item>
      <title>Biotia Selected By Mayo Clinic Platform To Accelerate The Success of Its AI Diagnostic Software</title>
      <link>https://www.biospace.com/biotia-selected-by-mayo-clinic-platform-to-accelerate-the-success-of-its-ai-diagnostic-software</link>
      <description>Mayo Clinic Platform, a strategic initiative to improve health care through insights and knowledge derived from data, has selected Biotia, a company fighting infectious diseases powered through genomics and artificial intelligence (AI), to join its Accelerate program with a focus on model validation and clinical readiness.</description>
      <pubDate>Mon, 15 Aug 2022 15:40:15 GMT</pubDate>
      <guid>https://www.biospace.com/biotia-selected-by-mayo-clinic-platform-to-accelerate-the-success-of-its-ai-diagnostic-software</guid>
    </item>
    <item>
      <title>Biotia, Pioneering Pathogen Detection Company, Raises an Oversubscribed $8M Series A</title>
      <link>https://www.biospace.com/biotia-pioneering-pathogen-detection-company-raises-an-oversubscribed-8m-series-a</link>
      <description>New York, NY -- August 23, 2022 -- Biotia, a company fighting infectious diseases powered by genomics and artificial intelligence (AI), has raised an oversubscribed $8 million Series A round led by OCA Ventures.</description>
      <pubDate>Tue, 23 Aug 2022 17:15:21 GMT</pubDate>
      <guid>https://www.biospace.com/biotia-pioneering-pathogen-detection-company-raises-an-oversubscribed-8m-series-a</guid>
    </item>
    <item>
      <title>Biotia, Pioneering Pathogen Detection Company, Raises $2.4M Seed Round, Expands Scientific Advisory Board</title>
      <link>https://www.biospace.com/biotia-pioneering-pathogen-detection-company-raises-2-4m-seed-round-expands-scientific-advisory-board</link>
      <description>Biotia, a health tech company leveraging next-generation DNA sequencing (NGS) and artificial intelligence (AI) software for precision infectious disease detection and diagnosis, today announced an oversubscribed $2.4M seed raise and expanded scientific advisory board .</description>
      <pubDate>Tue, 10 Dec 2019 12:46:05 GMT</pubDate>
      <guid>https://www.biospace.com/biotia-pioneering-pathogen-detection-company-raises-2-4m-seed-round-expands-scientific-advisory-board</guid>
    </item>
    <item>
      <title>Biotia Gets First-Ever NY State Regulatory Approval for a Urine Infectious Disease Test Powered by Genomics and AI</title>
      <link>https://www.biospace.com/press-releases/biotia-gets-first-ever-ny-state-regulatory-approval-for-a-urine-infectious-disease-test-powered-by-genomics-and-ai</link>
      <description />
      <pubDate>Tue, 05 Nov 2024 08:03:33 GMT</pubDate>
      <guid>https://www.biospace.com/press-releases/biotia-gets-first-ever-ny-state-regulatory-approval-for-a-urine-infectious-disease-test-powered-by-genomics-and-ai</guid>
    </item>
    <item>
      <title>Biotia Announces Collaboration with Mayo Clinic to Advance Microbial Identification for Infectious Disease Diagnostics</title>
      <link>https://www.biospace.com/press-releases/biotia-announces-collaboration-with-mayo-clinic-to-advance-microbial-identification-for-infectious-disease-diagnostics</link>
      <description />
      <pubDate>Thu, 03 Apr 2025 07:38:40 GMT</pubDate>
      <guid>https://www.biospace.com/press-releases/biotia-announces-collaboration-with-mayo-clinic-to-advance-microbial-identification-for-infectious-disease-diagnostics</guid>
    </item>
    <item>
      <title>Biotia Publishes Clinical Validation of Advanced UTI Test in Leading Microbiology Journal</title>
      <link>https://www.biospace.com/press-releases/biotia-publishes-clinical-validation-of-advanced-uti-test-in-leading-microbiology-journal</link>
      <description />
      <pubDate>Fri, 24 Apr 2026 01:49:50 GMT</pubDate>
      <guid>https://www.biospace.com/press-releases/biotia-publishes-clinical-validation-of-advanced-uti-test-in-leading-microbiology-journal</guid>
    </item>
  </channel>
</rss>
